CD19 and lymphoma: The presence of emapalumab in the culture did not cause any significant modification of the cytotoxicity exerted by CAR.CD19-T cells toward CD19+ lymphoma cells (Effector:Target, E:T ratio of 1:1) in vitro, as compared to untreated conditions, at any of the tested concentrations (Fig. 1a for Daudi model and Supplementary Fig. 1a for Raji model).